Close Menu

NEW YORK — Curetis reported on Thursday a nearly 17 percent increase in preliminary revenues for the first nine months of 2019 based on increasing demand for its Unyvero molecular diagnostics system and test cartridges, as well as bioinformatics services from its Ares Genetics subsidiary.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.